Literature DB >> 3191941

The effects of the 5 HT2 antagonist ketanserin in adult atopic asthma.

D J Stott1, J A Roberts, N C Thomson, S G Ball.   

Abstract

We have studied eight adult atopic asthmatic patients in a randomized double-blind, placebo-controlled, cross-over trial in order to examine the effects of the 5 HT2 antagonist ketanserin on airways function (FEV1, FVC, V50(chi), and V25(pi]. Ketanserin did not significantly change resting bronchomotor tone. Treadmill exercise caused a similar maximal percentage fall in FEV1 after both drug [16.8 (3.7)%] and placebo [19.2 (4.2)%]; ketanserin did not significantly attenuate bronchoconstriction, measured over a 20-min period after exercise. These results suggest that 5 HT2 receptors do not play a major role in the control of resting bronchomotor tone or in exercise-induced bronchoconstriction in adult atopic asthmatic patients.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3191941     DOI： 10.1007/bf00609255

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  18 in total

Review 1.  Antihypertensive mode of action of ketanserin.

Authors:  J I Robertson; D J Stott; S G Ball
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

2.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

3.  Role of smooth muscle alpha 1-receptors in nonspecific bronchial responsiveness in asthma.

Authors:  N C Thomson; E E Daniel; F E Hargreave
Journal:  Am Rev Respir Dis       Date:  1982-09

4.  Platelet activation during antigen-induced airway reactions in asthmatic subjects.

Authors:  K A Knauer; L M Lichtenstein; N F Adkinson; J E Fish
Journal:  N Engl J Med       Date:  1981-06-04       Impact factor: 91.245

5.  Ketanserin, a new blocking agent of serotonin S2-receptors. Respiratory functional effects in chronic obstruction of the airways.

Authors:  M Cazzola; G D'Amato; G Lobefalo; B Guillaro; J Sepe; G Assogna; R Pietroletti; D Lauria
Journal:  Chest       Date:  1987-11       Impact factor: 9.410

6.  Inhaled prazosin in asthma.

Authors:  P J Barnes; P W Ind; C T Dollery
Journal:  Thorax       Date:  1981-05       Impact factor: 9.139

7.  The effect of inhaled 5-hydroxytryptamine (5-HT, serotonin) on airway calibre in man.

Authors:  M J Cushley; L H Wee; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

8.  Content and subcellular localization of catecholamines and 5-hydroxytryptamine in human and animal blood platelets: monoamine distribution between platelets and plasma.

Authors:  M Da Prada; G B Picotti
Journal:  Br J Pharmacol       Date:  1979-04       Impact factor: 8.739

9.  A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1 receptors.

Authors:  P R Saxena; A Lawang
Journal:  Arch Int Pharmacodyn Ther       Date:  1985-10

10.  Bronchial challenge with serotonin in asthmatics.

Authors:  P Tønnesen
Journal:  Allergy       Date:  1985-02       Impact factor: 13.146
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.